Symbols / INBX Stock $130.67 -0.60% Inhibrx Biosciences, Inc.

Healthcare • Biotechnology • United States • NMS
INBX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Mark Paul Lappe
Exch · Country NMS · United States
Market Cap 1.91B
Enterprise Value 1.89B
Income -140.06M
Sales 1.30M
FCF (ttm) -84.46M
Book/sh 0.55
Cash/sh 8.50
Employees 109
Insider 10d —
IPO May 29, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -46.83
PEG —
P/S 1,468.20
P/B 238.44
P/C —
EV/EBITDA -14.27
EV/Sales 1,454.94
Quick Ratio 3.68
Current Ratio 3.93
Debt/Eq 1,338.82
LT Debt/Eq —
EPS (ttm) -9.04
EPS next Y -2.79
EPS Growth —
Revenue Growth -100.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-19
ROA -51.58%
ROE -197.85%
ROIC —
Gross Margin 0.00%
Oper. Margin -103.87%
Profit Margin 0.00%
Shs Outstand 14.61M
Shs Float 7.81M
Insider Own 23.26%
Instit Own 81.78%
Short Float 19.58%
Short Ratio 8.56
Short Interest 2.14M
52W High 155.29
vs 52W High -15.86%
52W Low 10.84
vs 52W Low 1,105.40%
Beta —
Impl. Vol. 1.50%
Rel Volume 1.29
Avg Volume 290.34K
Volume 374.99K
Target (mean) $300.00
Tgt Median $300.00
Tgt Low $300.00
Tgt High $300.00
# Analysts 1
Recom Buy
Prev Close $131.45
Price $130.66
Change -0.60%
About

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$300.00
Mean price target
2. Current target
$130.67
Latest analyst target
3. DCF / Fair value
$-104.07
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$130.67
Low
$300.00
High
$300.00
Mean
$300.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-08 init Stifel — → Buy $150
2025-08-22 reit JMP Securities Market Perform → Market Perform —
2025-05-15 reit JMP Securities Market Perform → Market Perform —
2025-03-18 reit Citizens Capital Markets Market Perform → Market Perform —
2025-01-22 reit JMP Securities Market Perform → Market Perform —
2024-07-23 init JMP Securities — → Market Perform —
2024-01-23 down JMP Securities Market Outperform → Market Perform —
2023-11-20 reit JMP Securities Market Outperform → Market Outperform $27
2023-08-23 main JMP Securities Outperform → Outperform $27
2023-05-10 reit JMP Securities — → Market Outperform $35
2023-03-08 main JMP Securities — → Market Outperform $35
2023-03-07 reit Credit Suisse — → Outperform $46
2022-11-08 main Credit Suisse — → Outperform $46
2022-10-05 main Evercore ISI Group — → Outperform $60
2022-08-09 main Credit Suisse — → Outperform $48
2022-03-16 init SMBC Nikko — → Outperform $40
2022-03-02 main JMP Securities — → Market Outperform $40
2021-11-10 main Credit Suisse — → Outperform $53
2021-11-02 main JMP Securities — → Market Outperform $53
2021-09-21 init JMP Securities — → Market Outperform $46
News
RSS: Latest INBX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-07 VIKING GLOBAL INVESTORS LP Beneficial Owner of more than 10% of a Class of Security — 350,000 $32.25 $11,287,500
2025-03-27 KAYYEM JON FAIZ Director — 90,000 $0.00 $0
2024-12-16 KAYYEM JON FAIZ Director — 500,000 $0.00 $0
2024-12-06 KAYYEM JON FAIZ Director — 52,000 $0.00 $0
2024-11-20 KAYYEM JON FAIZ Director — 107,186 $14.19 $1,523,620
2024-10-03 VUORI KRISTIINA S. Director — 6,667 $15.00 $100,005
2024-09-16 LAPPE MARK Chief Executive Officer — 40,000 $15.05 $629,117
2024-09-11 VUORI KRISTIINA S. Director — 6,636 $15.00 $99,992
2024-09-10 LAPPE MARK Chief Executive Officer — 44,000 $15.19 $671,150
2024-09-03 LAPPE MARK Chief Executive Officer — 40,000 $14.02 $596,763
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.30
+550.00%
0.20
-88.89%
1.80
+38.36%
1.30
Operating Revenue
1.30
+550.00%
0.20
-88.89%
1.80
+38.36%
1.30
Operating Expense
136.32
-58.89%
331.65
+50.05%
221.02
+89.52%
116.62
Research And Development
113.03
-44.52%
203.74
+6.32%
191.64
+88.62%
101.60
Selling General And Administration
23.12
-81.87%
127.50
+333.96%
29.38
+95.42%
15.04
General And Administrative Expense
23.12
-81.87%
127.50
+333.96%
29.38
+95.42%
15.04
Other Gand A
23.12
-81.87%
127.50
+333.96%
29.38
+95.42%
15.04
Other Operating Expenses
—
—
—
-0.01
Total Expenses
136.32
-58.89%
331.65
+50.05%
221.02
+89.52%
116.62
Operating Income
-135.03
+59.26%
-331.45
-51.19%
-219.22
-90.09%
-115.32
Total Operating Income As Reported
-135.03
+59.26%
-331.45
-51.19%
-219.22
-90.09%
-115.32
EBITDA
-125.37
-107.36%
1,703.35
+924.10%
-206.69
-81.15%
-114.10
Normalized EBITDA
-125.37
+60.59%
-318.15
-53.92%
-206.69
-81.15%
-114.10
Reconciled Depreciation
2.48
+8.67%
2.29
+91.86%
1.19
-2.78%
1.23
EBIT
-127.86
-107.52%
1,701.07
+918.28%
-207.88
-80.26%
-115.32
Total Unusual Items
0.00
-100.00%
2,021.50
0.00
—
Total Unusual Items Excluding Goodwill
0.00
-100.00%
2,021.50
0.00
—
Special Income Charges
0.00
-100.00%
2,021.50
0.00
—
Restructuring And Mergern Acquisition
0.00
+100.00%
-2,021.50
0.00
—
Net Income
-140.06
-108.30%
1,687.57
+799.19%
-241.36
-109.29%
-115.33
Pretax Income
-140.05
-108.30%
1,687.57
+803.97%
-239.72
-107.87%
-115.32
Net Non Operating Interest Income Expense
-4.65
-82.16%
-2.55
+87.20%
-19.92
—
Interest Expense Non Operating
12.20
-9.60%
13.49
-57.63%
31.84
—
Net Interest Income
-4.65
-82.16%
-2.55
+87.20%
-19.92
—
Interest Expense
12.20
-9.60%
13.49
-57.63%
31.84
—
Interest Income Non Operating
7.55
-31.00%
10.94
-8.20%
11.92
—
Interest Income
7.55
-31.00%
10.94
-8.20%
11.92
—
Other Income Expense
-0.38
-100.02%
2,021.57
+348647.07%
-0.58
-58100.00%
0.00
Other Non Operating Income Expenses
-0.38
-608.00%
0.07
+112.93%
-0.58
-58100.00%
0.00
Tax Provision
0.00
+0.00%
0.00
-33.33%
0.00
+0.00%
0.00
Tax Rate For Calcs
0.00
+20999900.00%
0.00
-100.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-140.06
-108.30%
1,687.57
+799.19%
-241.36
-109.29%
-115.33
Net Income From Continuing Operation Net Minority Interest
-140.06
-108.30%
1,687.57
+799.19%
-241.36
-109.29%
-115.33
Net Income From Continuing And Discontinued Operation
-140.06
-108.30%
1,687.57
+799.19%
-241.36
-109.29%
-115.33
Net Income Continuous Operations
-140.06
-108.30%
1,687.57
+799.19%
-241.36
-109.29%
-115.33
Normalized Income
-140.06
+58.06%
-333.92
-38.35%
-241.36
-109.29%
-115.33
Net Income Common Stockholders
-140.06
-108.30%
1,687.57
+799.19%
-241.36
-109.29%
-115.33
Diluted EPS
-9.04
-108.03%
112.62
+764.50%
-16.95
-109.29%
-8.10
Basic EPS
-9.04
-107.93%
114.01
+772.70%
-16.95
-109.29%
-8.10
Basic Average Shares
15.49
+4.63%
14.80
+3.94%
14.24
+0.00%
14.24
Diluted Average Shares
15.49
+3.36%
14.98
+5.22%
14.24
+0.00%
14.24
Diluted NI Availto Com Stockholders
-140.06
-108.30%
1,687.57
+799.19%
-241.36
-109.29%
-115.33
Depreciation Amortization Depletion Income Statement
0.18
-55.69%
0.40
—
—
Depreciation And Amortization In Income Statement
0.18
-55.69%
0.40
—
—
Earnings From Equity Interest Net Of Tax
—
0.00
+100.00%
-1.63
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
146.48
-18.97%
180.77
-41.29%
307.89
+1749.76%
16.64
Current Assets
132.83
-17.19%
160.40
-45.69%
295.36
+4615.92%
6.26
Cash Cash Equivalents And Short Term Investments
124.22
-18.60%
152.60
-45.09%
277.92
—
Cash And Cash Equivalents
124.22
-18.60%
152.60
-45.09%
277.92
—
Receivables
0.18
-57.86%
0.42
-46.02%
0.78
+202.72%
0.26
Accounts Receivable
0.00
-100.00%
0.20
-74.29%
0.78
+220.16%
0.24
Other Receivables
0.18
-10.15%
0.20
—
—
Prepaid Assets
6.89
+11.48%
6.18
-60.26%
15.56
+191.86%
5.33
Other Current Assets
1.54
+28.63%
1.20
+9.51%
1.09
+62.31%
0.67
Total Non Current Assets
13.65
-33.01%
20.37
+62.50%
12.54
+20.74%
10.38
Net PPE
9.27
-31.54%
13.54
+44.47%
9.37
+29.83%
7.22
Gross PPE
20.39
-9.10%
22.43
+39.69%
16.06
+25.87%
12.76
Accumulated Depreciation
-11.12
-25.05%
-8.89
-32.99%
-6.69
-20.70%
-5.54
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
14.06
-1.67%
14.30
+57.59%
9.07
+19.38%
7.60
Construction In Progress
—
0.00
-100.00%
3.59
0.00
Other Properties
5.54
-24.57%
7.34
+148.58%
2.95
-37.42%
4.72
Leases
0.80
+0.00%
0.80
+80.27%
0.44
+0.00%
0.44
Other Non Current Assets
4.38
-35.91%
6.83
+115.90%
3.16
+0.00%
3.16
Total Liabilities Net Minority Interest
138.49
+193.51%
47.18
-82.15%
264.39
+1004.16%
23.95
Current Liabilities
33.80
-17.02%
40.73
-27.67%
56.31
+171.10%
20.77
Payables And Accrued Expenses
24.02
-23.52%
31.41
-34.21%
47.74
+207.27%
15.54
Payables
5.94
-35.71%
9.24
-15.60%
10.95
+152.22%
4.34
Accounts Payable
5.94
-35.71%
9.24
-15.60%
10.95
+152.22%
4.34
Current Accrued Expenses
18.08
-18.43%
22.16
-39.75%
36.79
+228.62%
11.20
Pensionand Other Post Retirement Benefit Plans Current
7.45
-3.57%
7.73
+18.75%
6.51
+92.83%
3.37
Current Debt And Capital Lease Obligation
2.33
+45.83%
1.59
-22.69%
2.06
+10.91%
1.86
Current Capital Lease Obligation
2.33
+45.83%
1.59
-22.69%
2.06
+10.91%
1.86
Total Non Current Liabilities Net Minority Interest
104.69
+1522.28%
6.45
-96.90%
208.08
+6457.77%
3.17
Long Term Debt And Capital Lease Obligation
104.69
+1522.28%
6.45
-96.90%
208.08
+6457.77%
3.17
Long Term Debt
100.56
—
206.97
—
Long Term Capital Lease Obligation
4.13
-36.05%
6.45
+481.35%
1.11
-65.02%
3.17
Stockholders Equity
7.99
-94.02%
133.58
+207.07%
43.50
+695.93%
-7.30
Common Stock Equity
7.99
-94.02%
133.58
+207.07%
43.50
+695.93%
-7.30
Capital Stock
0.00
+0.00%
0.00
-80.00%
0.01
—
Common Stock
0.00
+0.00%
0.00
-80.00%
0.01
—
Preferred Stock
0.00
0.00
0.00
—
Share Issued
14.58
+0.70%
14.48
+1.65%
14.24
+0.00%
14.24
Ordinary Shares Number
14.58
+0.70%
14.48
+1.65%
14.24
+0.00%
14.24
Additional Paid In Capital
254.18
+6.03%
239.72
-63.53%
657.23
—
Retained Earnings
-246.19
-131.96%
-106.13
+82.71%
-613.73
—
Total Equity Gross Minority Interest
7.99
-94.02%
133.58
+207.07%
43.50
+695.93%
-7.30
Total Capitalization
108.55
-18.74%
133.58
-46.67%
250.47
+3531.11%
-7.30
Working Capital
99.03
-17.24%
119.67
-49.94%
239.05
+1747.57%
-14.51
Invested Capital
108.55
-18.74%
133.58
-46.67%
250.47
+3531.11%
-7.30
Total Debt
107.01
+1229.67%
8.05
-96.17%
210.14
+4075.26%
5.03
Capital Lease Obligations
6.45
-19.82%
8.05
+153.64%
3.17
-36.96%
5.03
Net Tangible Assets
7.99
-94.02%
133.58
+207.07%
43.50
+695.93%
-7.30
Tangible Book Value
7.99
-94.02%
133.58
+207.07%
43.50
+695.93%
-7.30
Duefrom Related Parties Current
0.00
-100.00%
0.02
0.00
-100.00%
0.01
Interest Payable
0.86
0.00
-100.00%
2.35
—
Other Equity Interest
—
—
-7.97
-9.22%
-7.30
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-129.79
+33.24%
-194.41
-0.57%
-193.31
-112.87%
-90.81
Cash Flow From Continuing Operating Activities
-129.79
+33.24%
-194.41
-0.57%
-193.31
-112.87%
-90.81
Net Income From Continuing Operations
-140.06
-108.30%
1,687.57
+799.19%
-241.36
-109.29%
-115.33
Depreciation Amortization Depletion
2.48
+8.67%
2.29
+91.86%
1.19
-2.78%
1.23
Depreciation And Amortization
2.48
+8.67%
2.29
+91.86%
1.19
-2.78%
1.23
Other Non Cash Items
4.24
+7.07%
3.96
-21.23%
5.03
+210.30%
1.62
Stock Based Compensation
11.14
-80.97%
58.52
+135.52%
24.85
+39.65%
17.79
Operating Gains Losses
0.01
+100.00%
-1,998.80
-122201.22%
1.64
+8515.79%
0.02
Gain Loss On Sale Of PPE
0.01
+0.00%
0.01
+300.00%
0.00
-84.21%
0.02
Change In Working Capital
-7.61
-114.63%
52.05
+239.14%
15.35
+297.82%
3.86
Change In Receivables
0.24
-32.12%
0.36
+168.71%
-0.52
-183.90%
0.62
Changes In Account Receivables
0.20
+208.11%
-0.18
+65.42%
-0.54
-511.54%
0.13
Change In Prepaid Assets
1.40
-53.05%
2.98
+128.99%
-10.29
-2627.03%
0.41
Change In Payables And Accrued Expense
-7.66
-114.25%
53.79
+90.87%
28.18
+307.05%
6.92
Change In Accrued Expense
-4.36
-112.15%
35.88
+37.64%
26.07
+257.09%
7.30
Change In Payable
-3.30
-118.44%
17.90
+748.89%
2.11
+657.94%
-0.38
Change In Account Payable
-3.30
-118.44%
17.90
+748.89%
2.11
+657.94%
-0.38
Change In Other Working Capital
—
—
-0.17
+84.94%
-1.10
Change In Other Current Assets
0.00
+100.00%
-3.67
0.00
+100.00%
-1.32
Change In Other Current Liabilities
-1.59
-13.28%
-1.41
+24.30%
-1.86
-11.11%
-1.67
Investing Cash Flow
-0.03
+98.92%
-2.60
+43.46%
-4.59
-569.53%
-0.69
Cash Flow From Continuing Investing Activities
-0.03
+98.92%
-2.60
+43.46%
-4.59
-569.53%
-0.69
Net PPE Purchase And Sale
-0.03
+98.92%
-2.60
+43.46%
-4.59
-569.53%
-0.69
Purchase Of PPE
-0.03
+98.81%
-2.60
+43.46%
-4.59
-569.53%
-0.69
Sale Of PPE
0.00
0.00
—
—
Capital Expenditure
-0.03
+98.81%
-2.60
+43.46%
-4.59
-569.53%
-0.69
Gain Loss On Sale Of Business
0.00
+100.00%
-1,998.81
0.00
—
Financing Cash Flow
101.45
+41.53%
71.68
-64.51%
201.96
+120.73%
91.50
Cash Flow From Continuing Financing Activities
101.45
+41.53%
71.68
-64.51%
201.96
+120.73%
91.50
Net Issuance Payments Of Debt
99.97
0.00
—
—
Issuance Of Debt
99.97
0.00
—
—
Long Term Debt Issuance
99.97
0.00
—
—
Net Long Term Debt Issuance
99.97
0.00
—
—
Net Common Stock Issuance
—
0.00
-100.00%
200.00
—
Proceeds From Stock Option Exercised
1.61
-97.76%
71.68
+2994.91%
2.32
—
Net Other Financing Charges
-0.12
—
-0.35
-100.39%
91.50
Changes In Cash
-28.38
+77.36%
-125.33
-3187.66%
4.06
—
Beginning Cash Position
152.60
-45.09%
277.92
+1.48%
273.87
0.00
End Cash Position
124.22
-18.60%
152.60
-45.09%
277.92
0.00
Free Cash Flow
-129.82
+34.10%
-197.01
+0.45%
-197.90
-116.29%
-91.50
Interest Paid Supplemental Data
8.90
-22.65%
11.51
-56.93%
26.72
—
Income Tax Paid Supplemental Data
0.00
+0.00%
0.00
-33.33%
0.00
-25.00%
0.00
Common Stock Issuance
—
0.00
-100.00%
200.00
—
Earnings Losses From Equity Investments
—
0.00
-100.00%
1.63
0.00
Issuance Of Capital Stock
—
0.00
-100.00%
200.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category